Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care. The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide. Read More
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 13.5% in the morning session after the company reported disappointing third-quarter financial results, which included a miss on revenue and a weak outlook.
Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.
NEW YORK - October 30, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. (NYSE: BAX) of a class action securities lawsuit.
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Baxter (BAX) Q3 2025 earnings beat EPS estimates but revenue missed forecasts. The stock fell sharply on the revenue miss and a cautious Q4 sales outlook.
Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).
NEW YORK - October 29, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. (NYSE: BAX) of a class action securities lawsuit.
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Baxter International, Inc. (“Baxter” or the “Company”) (NYSE:BAX) investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a pending federal securities class action.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”). Baxter investors have until December 15, 2025 to file a lead plaintiff motion.
